Alle Studien
Aktiv, aber nicht rekrutierendPHASE3INTERVENTIONELL

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

This research study is investigating a drug called erenumab for children and teenagers between 6 and 17 years old who experience episodic migraines. Episodic migraines mean headaches that occur less than 15 days a month. The main aim is to see if erenumab can effectively reduce how often these young people get migraines compared to a dummy treatment (placebo). We also want to make sure the medicine is safe. Participants will receive different doses of erenumab or a placebo as a monthly injection. This is a "Phase 3" study, which means it's a larger study designed to confirm the medicine's benefits and safety before it might become more widely available.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE3
Sponsor
Amgen
Einschreibeziel
457
Starten
19 Jul 2019
Geschätzte Fertigstellung
19 Nov 2026

Worum geht es in dieser Studie?

Migraine headaches can be really tough for anyone, and especially for children and teenagers. This study is looking into a medicine called erenumab. It's hoped that erenumab can help prevent migraines from happening so often in young people aged 6 to 17. There are different types of migraines, and this study is focusing on 'episodic migraine', which means people who get migraines less than 15 days a month.

The main question this study wants to answer is simple: can erenumab reduce the number of migraine days a young person experiences each month? We also need to know if the medicine is safe to use. To do this, some participants will receive erenumab, while others will receive a 'placebo' – a treatment that looks just like erenumab but contains no active medicine. This helps researchers understand if the changes they see are truly due to the medicine or something else. Neither the participants, their families, nor the doctors will know who is getting which treatment during the main part of the study; this is called 'double-blind'.

By carefully comparing the results from the erenumab groups and the placebo group, the researchers hope to gather strong evidence about whether erenumab is a safe and effective option for preventing migraines in young people. Finding better ways to manage migraines could greatly improve the daily lives of children and teenagers who suffer from them.

Wichtige Erkenntnisse

  • This study is testing a new migraine prevention medicine for children and teenagers.
  • It aims to see if erenumab can reduce how often young people get migraines.
  • Participants will receive either the active medicine or a 'dummy' treatment (placebo).
  • The medicine is given by monthly injection under the skin.
  • The study will check both how well the medicine works and if it's safe.
  • The study lasts for many months, including screening, treatment, and follow-up.

Wer könnte berechtigt sein?

To join this study, we are looking for children and teenagers between 6 and 17 years old. If you're under 18, a parent or legal guardian will need to give their permission for you to take part, and you'll also be asked if you're happy to join. You should have a history of migraines for at least 12 months, and these migraines should have been confirmed by a doctor.

Your migraines should be 'episodic', meaning you typically get fewer than 15 headache days a month. For at least 4 of those headache days each month, your headaches should be what you'd consider a migraine. We'll check this over a few months before you officially start the study medicine.

Migraines in children can sometimes look a bit different from adults. For example, headaches might last anywhere from 2 to 72 hours, and pain is often on both sides of the head rather than just one. These special considerations for younger people will be taken into account when deciding if the study is right for you.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you between 6 and 17 years old?
  2. Do your parents or legal guardians agree for you to take part?
  3. Have you had migraines for at least one year?
  4. Do you usually have fewer than 15 headache days per month?
  5. Are at least 4 of those headache days migraine days each month?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, the study will involve several steps over a period of time. First, there's a 'screening' phase which lasts about 7 weeks. This period includes checking if you're suitable for the study and recording your migraine headaches for 4 weeks to understand your usual pattern.

After screening, you'll enter the main 'double-blind treatment phase'. This part lasts either 12 or 24 weeks, depending on which group you are in. During this time, you will receive either erenumab or a placebo as an injection just under the skin, once a month. The dose of erenumab will depend on your body weight.

Following the main treatment phase, there's an optional 'extension phase' for up to 40 additional weeks, where all participants will receive erenumab. Finally, there's a 12-week 'safety follow-up phase' to monitor your health after your last dose of the study medicine. Throughout the study, you'll have regular visits to the clinic and will be asked to keep a diary of your migraine days.

Potenzielle Risiken und Vorteile

Taking part in any medical study has both potential benefits and potential risks. A potential benefit of this study is that erenumab might help to reduce your migraines, improving your quality of life. You'll also receive careful medical attention throughout the study. However, like all medicines, erenumab could have side effects, which the study team will discuss with you. These could be mild, like pain at the injection site, or more serious. The placebo group will not receive the active drug, so they won't experience benefits from erenumab, but also won't have its side effects. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (119)

  • Paradigm Clinical Research Center Inc
    Verifizierte Postleitzahl
    San Diego, Vereinigte Staaten
  • Kinderkrankenhaus Colorado
    Verifizierte Postleitzahl
    Aurora, Vereinigte Staaten
  • Colorado Springs Neurological Associates
    Verifizierte Postleitzahl
    Colorado Springs, United States
  • New England Institute for Clinical Research
    Verifizierte Postleitzahl
    Stamford, United States
  • Childrens National Health System
    Verifizierte Postleitzahl
    Washington D.C., Vereinigte Staaten
  • Northwest Florida Clinical Research Group Limited Liability Company
    Verifizierte Postleitzahl
    Gulf Breeze, United States
  • Nicklaus Childrens Hospital
    Verifizierte Postleitzahl
    Miami, Vereinigte Staaten
  • Pediatric Epilepsy and Neurology Specialists
    Verifizierte Postleitzahl
    Tampa, Vereinigte Staaten
  • TrueBlue Clinical Research
    Verifizierte Postleitzahl
    Tampa, Vereinigte Staaten
  • Premiere Research Institute
    Verifizierte Postleitzahl
    West Palm Beach, Vereinigte Staaten
  • Rare Disease Research Center Pediatrics
    Verifizierte Postleitzahl
    Atlanta, Vereinigte Staaten
  • CenExel iResearch, LLC
    Verifizierte Postleitzahl
    Savannah, Vereinigte Staaten

Häufige Fragen

What is erenumab?

Erenumab is a medicine that blocks a specific protein in the body believed to play a key role in causing migraines. It's given as an injection.

What does 'episodic migraine' mean?

Episodic migraine means you get migraine headaches less than 15 days in a month. This study is for people who have this type of migraine.

Was ist ein 'Placebo'?

A placebo is a dummy treatment that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers compare the real medicine's effects.

Wie wird das Medikament verabreicht?

The study medicine (erenumab or placebo) will be given as an injection just under the skin once a month. The dose might be different depending on your weight.

Wie lange wird die Studie dauern?

The study involves a screening period, a main treatment phase of 12 or 24 weeks, an optional extension phase of 40 weeks, and a final safety follow-up of 12 weeks.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.